Active surveillance without prostate biopsy for low-risk suspects
Part of Cancer, Kidney & urinary clinical trials.
This study checks whether people with a low chance of prostate cancer can be monitored closely without having an immediate prostate biopsy. It uses PSA blood tests and prostate MRI to sort who may safely wait.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have signs that suggest possible prostate cancer and normally would need a biopsy
- You can have a PSA blood test and a prostate MRI (mpMRI) as part of screening
- Your total PSA level is between 4 and 10 (ng/mL)
- A prediction model (USTC) estimates your prostate cancer risk is under 0.05
- You do not have a family history of prostate cancer and you have no history of other cancers
- You have not had a prostate biopsy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether men with low-risk prostate cancer can safely avoid treatment by closely monitoring their cancer over many years. It tests a new approach to see if it is better than the current standard of care.
This study follows men with low-risk prostate cancer who choose active surveillance (watching closely instead of immediate treatment). It aims to better track which monitoring results stay reassuring over time, and when treatment might be needed.
This study tests whether watching low-risk prostate cancer closely (instead of treating right away) is safe. It may help some people avoid early treatments and their side effects while still keeping a close eye on the cancer.
This trial studies a “watchful waiting” approach, where doctors closely monitor certain prostate cancers with regular checkups and repeat biopsies. It may help people avoid or delay treatment side effects while watching for signs the cancer needs treatment.
This is a registry study that follows men with low-risk prostate cancer who choose active surveillance instead of immediate treatment. It helps doctors understand how safe and effective active surveillance is, including confirming results with repeat biopsies.
This study checks whether a special prostate scan called PSMA PET-CT (along with standard monitoring scans) can help guide care while you are on “active surveillance” instead of immediate treatment. It may help doctors track low-risk prostate cancer changes more accurately over time.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.